| Identification | Back Directory | [Name]
1,3-dihydro-1-hydroxy-2,1-Benzoxaborole-7-propanoic acid | [CAS]
1268335-33-6 | [Synonyms]
AN3661
1,3-dihydro-1-hydroxy-2,1-Benzoxaborole-7-propanoic acid
3-(1-Hydroxy-1,3-dihydro-2,1-benzoxaborol-7-yl)propanoic acid
3-(1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-7-yl)propanoic acid | [Molecular Formula]
C10H11BO4 | [MDL Number]
MFCD22393432 | [MOL File]
1268335-33-6.mol | [Molecular Weight]
206 |
| Chemical Properties | Back Directory | [Melting point ]
150-151 °C | [Boiling point ]
402.7±55.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (1213.59 mM) | [form ]
Solid | [pka]
4.52±0.10(Predicted) | [color ]
White to off-white | [InChI]
1S/C10H11BO4/c12-9(13)5-4-7-2-1-3-8-6-15-11(14)10(7)8/h1-3,14H,4-6H2,(H,12,13) | [InChIKey]
CEVOKIPNIZQANN-UHFFFAOYSA-N | [SMILES]
OC(CCC1=CC=CC2=C1B(OC2)O)=O |
| Hazard Information | Back Directory | [Uses]
AN3661, a potent antimalarial lead compound, targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue subunit 3 (PfCPSF3). AN3661 inhibits Plasmodium falciparum laboratory-adapted strains (mean IC50=32 nM), Ugandan field isolates (mean ex vivo IC50=64 nM), and murine P. berghei and P. falciparum infections[1]. | [Biological Activity]
AN3661, a potent antimalarial lead compound, targets Plasmodium falciparum cleavage and polyadenylate-specific factor homolog subunit 3 (PfCPSF3). It inhibits infection of laboratory-adapted strains of Plasmodium falciparum (mean IC50=32 nM), Ugandan field isolates (mean IC50=64 nM) and mice P. berghei and P. falciparum. | [in vitro]
AN3661 is active at nanomolar (IC 50 =20-56 nM) concentrations against P. falciparum laboratory strains known to be sensitive (3D7) or resistant (W2, Dd2, K1, HB3, FCR3 and TM90C2B), and AN3661 is similarly active in ex vivo studies of fresh Ugandan field isolates (mean ex vivo IC 50 =64 nM). AN3661 shows minimal cytotoxicity against mammalian cell lines, with the CC 50 60.5 μM against Jurkat cells, and all other CC 50 values greater than the highest concentrations tested (25 μM or above).
AN3661 inhibits the stability of P. falciparum transcripts. | [in vivo]
AN3661 (50-200 mg.kg; po; daily for 4 days) inhibits murine P. berghei infections with ED 90 (4 days) 0.34 mg/kg.
AN3661 is administered orally for 4 days, beginning on the third day of infection, the ED 90 4 days after initiation of treatment is 0.57 mg/kg. < td class="col1 fwb"> Animal Model: | P. berghei -infected mice (malaria model) | | Dosage: | 50, 100, 200 mg/kg | | Administration: | Orally; daily for 4 days | | Result: | Rapidly controlled parasitemias, with an ED 90 of 0.34 mg/kg. Daily dosages of 50 mg/kg and 100 mg/kg extended survival, and mice treated with 200 mg/kg per day demonstrated long-term cures. | | [IC 50]
Plasmodium | [References]
[1] Sonoiki E, et al. A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Nat Commun. 2017;8:14574. Published 2017 Mar 6. DOI:10.1038/ncomms14574 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|